Lurking Beneath The Surface at HIMS
Something to think about if the FDA deems that GLP-1's are not in shortage.
(If you’re not yet among the growing number of premium subscribers to Herb On the Street and my Red Flag Alerts, and wonder why you should subscribe, I explain right here. Prices for new customers are going up to $300/year and $50/month on January 1. Thanks for supporting my work.)
If the FDA doesn’t once-again delay a ruling expected today, this could be a day of reckoning for investors in Hims & Hers HIMS 0.00%↑…
The ruling, unless it’s extended yet again, focuses on the hype and hope surrounding Hims: its sale compounded versions of the popular GLP-1 weight-loss drugs.
Typically brand names drugs like these can’t be compounded. They can’t, that is, unless the FDA has declared there is a shortage.
It did just that in October, but the trade group that represents the compounding industry sued the agency, which then deferred a final decision until… today.
Hims’ stock soared on the news…
But the underlying question remains: Is there still a shortage?
A report yesterday by Hunterbrook Media, which lays out the entire issue, says based on its research, there is no shortage.
Which gets to the bigger issue: Why investors in HIMS should worry if the FDA rules that there is no shortage.
I’ve laid out some of that in my own reports, including this one…
And in my initial Red Flag Alert below…
But to spare you the trouble of reading those, here’s a simpler way of looking at what’s lurking beneath the surface at Hims – and what’s at stake for investors…